Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Ascendis Pharma A/S files with the SEC in its annual reports.
In EUR millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
4.61
1.53
10.6
13.4
6.95
7.78
51.2
267
364
720
Cost of revenue
0
0
3.52
12.1
44.4
44.3
94.9
Gross profit
13.4
6.95
4.26
39
222
319
625
Research and development
66
99.6
140
192
261
296
380
413
307
304
Selling, general and administrative
11.5
13.5
25.1
48.5
76.7
160
221
264
291
458
Operating income
-72.9
-112
-155
-227
-331
-452
-562
-456
-279
-136
Interest expense
3.11
13.8
0.13
1.22
80.8
3.91
50.5
44.1
100
207
Interest income
7.3
0.92
24.7
17.8
1.81
59.7
52.2
43.9
25.6
114
Pre-tax income
-68.7
-124
-130
-218
-419
-384
-578
-474
-373
-213
Income tax
-0.23
-0.48
-0.39
-0.23
-0.22
-0.37
5.38
7.3
4.84
15.4
Income from continuing operations
-68.5
-124
Net income
-68.5
-124
-130
-218
-419
-384
-583
-481
-378
-228
EPS, basic
-2.58
-3.68
-3.17
-4.69
-8.28
-7.00
-10.40
-8.55
-6.53
-3.76
EPS, diluted
-2.58
-3.68
-3.17
-4.69
-8.28
-7.00
-10.40
-8.55
-6.53
-3.76
Balance sheet
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
180
195
278
598
585
446
445
392
560
616
Inventory
0
75.4
131
209
296
302
Total current assets
184
205
293
611
740
806
923
703
1,061
1,109
Property, plant and equipment
2.35
2.56
4.33
45.1
108
126
129
111
98.7
146
Lease right-of-use assets
18
12.5
11.2
30.9
Goodwill
3.5
3.5
3.5
3.5
Total assets
190
211
319
677
980
1,085
1,090
826
1,179
1,303
Accounts payable
13.1
23.8
Short-term debt
7
11.6
407
458
429
Total current liabilities
13.5
23.8
38.9
48
52.8
100
171
737
908
1,069
Lease liabilities
30.7
85.1
98
95.4
84.6
Total liabilities
13.5
23.8
38.9
79.6
141
201
826
971
1,285
1,465
Total debt
105
399
545
764
720
Total equity
177
187
280
597
839
884
263
-146
-106
-163
Total liabilities and equity
190
211
319
677
980
1,085
1,090
826
1,179
1,303
Cash flow statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-68.5
-124
-130
-218
-419
-384
-583
-481
-378
-228
Cash from operations
-60.2
-95.1
-139
-176
-272
-418
-496
-467
-306
53.9
Capital expenditures
-0.67
-0.94
-2.65
-5.16
-19.9
-23.7
-14.5
-2.44
Cash from investing
-0.67
-0.94
-2.65
-5.16
-291
-111
61.7
286
6.88
-8.49
Debt issued
0
503
136
134
0
Debt repaid
-6.36
-10.4
-11.4
-22
Stock issued
126
133
216
480
581
368
0
0
310
0
Share buybacks
-21.6
-105
0
0
-17.4
Cash from financing
117
125
203
494
603
351
397
134
444
36.3
Exchange rate effect
4.07
-13.7
20.7
7.75
-53.5
38.6
35.7
-6.01
22.8
-25.2
Free cash flow
-60.9
-96
-141
-181
-291
-441
-510
-470
Income taxes paid
-0.56
-0.15
-0.33
0.28
-1.1
-0.15
0
4.47
5.51
6.68
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Gross margin
86.8%
Gross profit / revenue.
Operating margin
-18.9%
Operating income / revenue.
Pre-tax margin
-29.5%
Pre-tax income / revenue.
Net margin
-31.7%
Net income / revenue.
Operating cash flow margin
7.5%
Cash from operations / revenue.
Return on assets (ROA)
-18.4%
Net income / average total assets.
R&D / revenue
42.2%
Research and development expense / revenue.
SG&A / revenue
63.6%
Selling, general and administrative expense / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
98.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
141.4%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
153.0%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
95.8%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
152.1%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
145.9%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
10.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
6.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
5.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.04x
Current assets / current liabilities.
Quick ratio
0.58x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.58x
(Cash + short-term investments) / current liabilities.
Debt / assets
55.3%
Total debt / total assets.
Liabilities / assets
112.5%
Total liabilities / total assets.
Net debt
€104.2M
Total debt - cash - short-term investments. Negative means more cash than debt.
Interest coverage
-0.66x
Operating income / interest expense.
Working capital
€39.6M
Current assets - current liabilities.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.58x
Revenue / average total assets.
Fixed asset turnover
5.87x
Revenue / average property, plant and equipment.
Inventory turnover
0.32x
Cost of revenue / average inventory.
Days inventory
1,148 days
365 x average inventory / cost of revenue.
Per share
Metric
Value
How it is calculated
EPS, diluted
-€3.76
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-€3.76
Net income per basic share, as reported (split-adjusted).
What was Ascendis Pharma A/S's revenue in fiscal 2025?
Ascendis Pharma A/S reported revenue of €720.1M for fiscal 2025, 98% higher than the year before.
Was Ascendis Pharma A/S profitable in fiscal 2025?
No. It reported a net loss of €228.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.